This ability may provide useful information for adaptive treatment schedules with anti-EGFR mAbs, since current dosing of cetuximab is based on the patient’s weight and the only confirmed clinical variable that predicts response to this agent is the grade of skin toxicity that occurs after treatment initiation (31,32). The gene discussed is EGFR; the disease is dermatological toxicity.